FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials

In the present study, we aim at providing an estimation of the impact of adding bevacizumab to FOLFOXIRI in an adjusted pooled analysis of two consecutive randomized trials in the first-line treatment of mCRC. Improved PFS and OS were reported with FOLFOXIRI plus bevacizumab when compared with FOLFOXIRI alone, with no differences in term of response rate, early response rate and depth of response.

from Cancer via ola Kala on Inoreader http://ift.tt/1QBIQzZ
via IFTTT